Rilotumumab Withdrawn Phase 2 Trials for Sarcomatous Mesothelioma / Recurrent Malignant Mesothelioma / Epithelial Mesothelioma / Advanced Malignant Mesothelioma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01105390AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma